Combining Forces to Hit Cancer Stem Cells: TRAIL-lymphocytes and EpCAMxCD3 Bispecific Antibody Show Efficacy Against Pancreatic Cancer
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endogenous immune responses and augments the effect of cytotoxic tumor therapy.
References
1.
Groth A, Salnikov A, Ottinger S, Gladkich J, Liu L, Kallifatidis G
. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting. Clin Cancer Res. 2012; 18(4):1028-38.
DOI: 10.1158/1078-0432.CCR-11-2767.
View
2.
Tolcher A, Mita M, Meropol N, von Mehren M, Patnaik A, Padavic K
. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol. 2007; 25(11):1390-5.
DOI: 10.1200/JCO.2006.08.8898.
View
3.
Cioffi M, Dorado J, Baeuerle P, Heeschen C
. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2011; 18(2):465-74.
DOI: 10.1158/1078-0432.CCR-11-1270.
View
4.
Hoffmann S, Wabnitz G, Samstag Y, Moldenhauer G, Ludwig T
. Functional analysis of bispecific antibody (EpCAMxCD3)-mediated T-lymphocyte and cancer cell interaction by single-cell force spectroscopy. Int J Cancer. 2010; 128(9):2096-104.
DOI: 10.1002/ijc.25556.
View
5.
Heiss M, Murawa P, Koralewski P, Kutarska E, Kolesnik O, Ivanchenko V
. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010; 127(9):2209-21.
PMC: 2958458.
DOI: 10.1002/ijc.25423.
View